Skip to content

News releases

The following are news releases and statements issued by Biosimilars Canada. News stories about biosimilars that may be of interest to readers are available here.

Canada’s Largest Public Drug Plan Announces Transition to Cost-Saving Biosimilar Medicines

Biosimilars Canada, a national association representing Canada’s biosimilar medicines industry, today welcomed the announcement by Ontario Health Minister Sylvia Jones that the province will implement a “switching” or transitioning policy to expand the use of biosimilar biologic medicines for the Ontario Drug Benefit (ODB) program in 2023.
Read more

The Value of Biosimilars for Public Drug Plans

There are few solutions to such healthcare challenges that allow governments to provide more value to taxpayers for the same dollars. But that is precisely the value proposition provided through the expanded use of biosimilar medicines.
Read more

Saskatchewan Becomes Sixth Province to Implement Biosimilar Switching Initiative

Toronto – October 20, 2022 – Biosimilars Canada, a national association representing Canada’s biosimilar medicines industry, today welcomed the announcement by the Government of Saskatchewan that it will implement a “switching” or transitioning policy to expand the use of biosimilar...
Read more

“Make the switch”: Biosimilars Canada pitches Ontario on savings, benefits of switching to biosimilars

Biosimilars Canada hosted a press conference at Queen’s Park, calling on the government of Premier Doug Ford to implement a biosimilars switching policy.
Read more

Nova Scotia Becomes Fifth Province to Implement Biosimilar Switching Initiative

Biosimilars Canada welcomes the announcement by the Government of Nova Scotia that it will implement a “switching” or transitioning policy to expand the use of biosimilar medicines under its public drug programs.
Read more

Northwest Territories Becomes Fifth Jurisdiction in Canada to Implement Biosimilar Switching Initiative

Biosimilars Canada, a national association representing Canada’s biosimilar medicines industry, today welcomed the announcement by the Government of the Northwest Territories that it will implement a “switching” or transitioning policy to expand the use of biosimilar medicines under its public drug programs.
Read more